Xenetic-Santersus share exchange values combined company at $141M; XBIO holders ~15%

Xenetic Biosciences, Inc.

Deal values Xenetic at ~$21M (15% pro forma) and Santersus at ~$120M (85%); 2,546,699 XBIO shares outstanding.
Expected to close Q4 2026; combined company to trade on Nasdaq under ticker SNTS.
NucleoCapture holds two FDA Breakthrough Device Designations; 80+ compassionate-use cases showed positive outcomes with no adverse events.
Lead sepsis program (~$5.6B market) targets potential EU launch in Q2 2028; CAR T lymphoma efficacy data expected Q2 2027.
Santersus options assumed by Xenetic; $0 net cash assumed, subject to adjustment per Share Exchange Agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.